Beta 2 agonists and asthma.

Addition of intravenous beta(2)-agonists to inhaled beta(2)-agonists for acute asthma.

BACKGROUND Inhaled beta-agonist therapy is central to the management of acute asthma. This review evaluates the benefit of an additional use of intravenous beta(2)-agonist agents. OBJECTIVES To determine the benefit of adding intravenous (IV) beta(2)-agonists to inhaled beta(2)-agonist therapy for acute asthma treated in the emergency department. SEARCH METHODS Randomised controlled trials ...

Safety of Long - Acting Beta - Agonists in Asthma ASTHMA THERAPY

THE EUROPEAN JOURNAL OF RESPIRATORY MEDICINE VOL I ISSUE I Although there was no attempt to determine degree of adherence with ICS at randomisation or persistence in their use during the course of the study, no significant differences were seen for primary events and asthma-related events, including deaths in the total population of patients receiving ICS at baseline. However, in the total popu...

Beta-agonists and asthma research: an international consultation.

The McGill Pharmacoepidemiology Programme invited academics from around the globe to Sarasota, Florida, in order to discuss recent research on betaagonist bronchodilators in the treatment of asthma. The purpose of the meeting was the development of a research agenda to deal with unanswered questions in the medium and long term. The meeting was sponsored by AB Astra, Boehringer lngelheim GmbH, F...

Beta-agonists and asthma: too much of a good thing?

In an unusual paradox, asthmatics who are chronically treated with bronchodilating beta-agonists sometimes experience a worsening of their condition. A new study describes one possible mechanism and reveals a potential new therapeutic target in the treatment of asthma.

Long acting beta 2 agonists and the risk of life threatening asthma.